Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (81-90 of 209) with videos related to

Pageof 21
Sort By:
Acta Dermato-Venereologica|January 25, 2018
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 InhibitorGil Yosipovitch, Linda F Gold, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2016
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic DermatitisKurt Jarnagin, Sanjay Chanda, Dina Coronado, et al.
Vaccines|February 28, 2023
COVID-19 Vaccine-Induced Lichenoid Eruptions-Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the LiteratureYonatan K Sapadin, Elazar Mermelstein, Robert G Phelps, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque PsoriasisAndrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Cutis|October 17, 2008
What the National Psoriasis Foundation means to dermatologists and our patientsElizabeth D Kaufman, Mark G Lebwohl, Gerald G Krueger, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque PsoriasisJeffrey L Sugarman, Linda Stein Gold, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|October 14, 2023
Generalized pustular psoriasis: A consensus statement from the National Psoriasis FoundationApril W Armstrong, Carly A Elston, Boni E Elewski, et al.
Dermatology and Therapy|June 9, 2021
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic BenefitsMark G Lebwohl, Emil A Tanghetti, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|September 25, 2002
Clinical effect of imiquimod 5% cream in the treatment of actinic keratosisAndrea N Persaud, Eleonora Shamuelova, Daniel Sherer, et al.
Journal of the American Academy of Dermatology|April 26, 2026
Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX"Harrison P Nguyen, Eingun James Song, Edward Ted Lain, et al.
Pageof 21

Showing results (81-90 of 209) with videos related to

Sort By:
Pageof 21
Acta Dermato-Venereologica|January 25, 2018
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 InhibitorGil Yosipovitch, Linda F Gold, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2016
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic DermatitisKurt Jarnagin, Sanjay Chanda, Dina Coronado, et al.
Vaccines|February 28, 2023
COVID-19 Vaccine-Induced Lichenoid Eruptions-Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the LiteratureYonatan K Sapadin, Elazar Mermelstein, Robert G Phelps, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque PsoriasisAndrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Cutis|October 17, 2008
What the National Psoriasis Foundation means to dermatologists and our patientsElizabeth D Kaufman, Mark G Lebwohl, Gerald G Krueger, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque PsoriasisJeffrey L Sugarman, Linda Stein Gold, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|October 14, 2023
Generalized pustular psoriasis: A consensus statement from the National Psoriasis FoundationApril W Armstrong, Carly A Elston, Boni E Elewski, et al.
Dermatology and Therapy|June 9, 2021
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic BenefitsMark G Lebwohl, Emil A Tanghetti, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|September 25, 2002
Clinical effect of imiquimod 5% cream in the treatment of actinic keratosisAndrea N Persaud, Eleonora Shamuelova, Daniel Sherer, et al.
Journal of the American Academy of Dermatology|April 26, 2026
Response to "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX"Harrison P Nguyen, Eingun James Song, Edward Ted Lain, et al.
Pageof 21